Nanotherapy for posterior eye diseases

作者: Indu Pal Kaur , Shilpa Kakkar

DOI: 10.1016/J.JCONREL.2014.05.031

关键词: Drug deliverySurgeryBlindnessComplete BlindnessBioinformaticsDrug moleculeEffective treatmentNanocarriersPosterior segment of eyeballTarget siteMedicine

摘要: It is assumed that more than 50% of the most enfeebling ocular diseases have their origin in posterior segment. Furthermore, these lead to partial or complete blindness, if left untreated. After cancer, blindness second dreaded disease world over. However, treatment eye challenging anterior segment ailments due a series anatomical barriers and physiological constraints confronted for delivery this In regard, nanostructured drug systems are proposed defy barriers, target retina, act as permeation enhancers addition providing controlled release. Since an important step towards developing effective strategies understand course route molecule needs follow reach site, first part present review discusses various pathways available clearance from eye. Promise held by nanocarrier systems, viz. liposomes, nanoparticles, nanoemulsion, selective targeting also discussed with illustrative examples, tables, flowcharts. applicability self-administration drops still unrealized dream which itself huge technological challenge.

参考文章(149)
G. A. Peyman, B. Khoobehi, Kwan-Rong Liu, Efficacy of liposome-bound amphotericin B for the treatment of experimental fungal endophthalmitis in rabbits. Investigative Ophthalmology & Visual Science. ,vol. 30, pp. 1527- 1534 ,(1989)
Henry F. Edelhauser, Dayle H. Geroski, Drug delivery for posterior segment eye disease. Investigative Ophthalmology & Visual Science. ,vol. 41, pp. 961- 964 ,(2000)
Amélie Bochot, Hélène Chacun, Valérie Boutet, Patrick Couvreur, Jean Robert Deverre, Jean Claude Jeanny, Elias Fattal, Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Investigative Ophthalmology & Visual Science. ,vol. 43, pp. 253- 259 ,(2002)
R N Weinreb, M Blumenkranz, K K Assil, M Nehorayan, T Ward, M Hartzer, Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes Investigative Ophthalmology & Visual Science. ,vol. 32, pp. 2891- 2897 ,(1991)
Tatsuji Yasuda, Nobuhiko Matsuo, Ikuya Masuda, Toshihiko Matsuo, Gene transfer with liposomes to the intraocular tissues by different routes of administration. Investigative Ophthalmology & Visual Science. ,vol. 37, pp. 1914- 1920 ,(1996)
U Pleyer, K D Nguyen, K Nguyen, B J Mondino, D Rückert, W J Jusko, S Lutz, M Narawane, V H Lee, Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye Investigative Ophthalmology & Visual Science. ,vol. 34, pp. 2737- 2742 ,(1993)
G A Peyman, T Lesar, P H Fishman, Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels. Investigative Ophthalmology & Visual Science. ,vol. 27, pp. 1103- 1106 ,(1986)
Leena Pitkänen, Marika Ruponen, Jenni Nieminen, Arto Urtti, Vitreous Is a Barrier in Nonviral Gene Transfer by Cationic Lipids and Polymers Pharmaceutical Research. ,vol. 20, pp. 576- 583 ,(2003) , 10.1023/A:1023238530504
Burkhard Wiechens, Doris Neumann, Joachim B. Grammer, Uwe Pleyer, Jürgen Hedderich, Gernot I.W. Duncker, Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes. International Ophthalmology. ,vol. 22, pp. 133- 143 ,(1998) , 10.1023/A:1006137100444
I Ahmed, T F Patton, Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Investigative Ophthalmology & Visual Science. ,vol. 26, pp. 584- 587 ,(1985)